Study to Estimate the Burden of Herpes Zoster (HZ) and Post-herpetic Neuralgia (PHN) in Italy

Herpes Zoster Clinical Trial

Official title:

Population Based Surveillance to Estimate the Burden of Herpes Zoster and Post-herpetic Neuralgia in Italy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01772160
• Other study ID #: 116208
• Status: Completed
• Start date: February 26, 2013
• Est. completion date: October 5, 2016

Study information

• Verified date: May 2020
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to collect data on the incidence, complications, economic burden and impact on the quality of life in adults aged ≥ 50 years with HZ disease in Italy.

Description:

The surveillance/recruitment period will take approximately 2 years and once the enrolment of HZ patients has ended, the study will continue for a maximum of 9 months to allow for completion of the follow-up of potential PHN cases.

The data will be captured at protocol specified time-points based on the time of enrolment of each subject.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 395
• Est. completion date: October 5, 2016
• Est. primary completion date: October 5, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• A male or female = 50 years of age at the time of study enrolment presenting with acute HZ.

• HZ diagnosis for this HZ episode:

• Is his/her first outpatient diagnosis (i.e. initial consultation), OR

• Took place at another site/centre (e.g. emergency room or Dermatologist/Specialist practice) provided the HZ diagnosis is not more than 7 days before the initial visit for the present study (i.e. secondary consultation).

• Written informed consent obtained from the patient.

• Ability to comply with study procedures.

Exclusion Criteria:

• Patient participating in another clinical study (participation in another observational, non-interventional trial is allowed).

Related Conditions & MeSH terms

• Herpes Zoster
• Herpes Zoster Vaccine
• Neuralgia
• Neuralgia, Postherpetic

Intervention

Other:
• Data collection
HZ/PHN booklet, HZ/PHN file and logbook. HZ/PHN booklet will be completed by the patient and the HZ/PHN file and logbook will be completed by the participating general practitioner.

Locations

Country	Name	City	State
Italy	GSK Investigational Site	Alessandria	Piemonte
Italy	GSK Investigational Site	Alessano (LE)
Italy	GSK Investigational Site	Angera (VA)	Lombardia
Italy	GSK Investigational Site	Arcidosso (GR)	Toscana
Italy	GSK Investigational Site	Arcisate (VA)	Lombardia
Italy	GSK Investigational Site	Arezzo	Toscana
Italy	GSK Investigational Site	Cavallino (LE)	Puglia
Italy	GSK Investigational Site	Civitella Paganico (GR)	Toscana
Italy	GSK Investigational Site	Comerio (VA)	Lombardia
Italy	GSK Investigational Site	Copertino (LE)	Puglia
Italy	GSK Investigational Site	Cutrofiano (LE)	Puglia
Italy	GSK Investigational Site	Fagnano Olona (VA)	Lombardia
Italy	GSK Investigational Site	Follonica (GR)	Toscana
Italy	GSK Investigational Site	Frugarolo (AL)	Piemonte
Italy	GSK Investigational Site	Galatina (LE)	Puglia
Italy	GSK Investigational Site	Ghirla Valganna (VA)	Lombardia
Italy	GSK Investigational Site	Grosseto	Toscana
Italy	GSK Investigational Site	Induno Olona (VA)	Lombardia
Italy	GSK Investigational Site	Lucignano (AR)	Toscana
Italy	GSK Investigational Site	Montesano S. (LE)	Puglia
Italy	GSK Investigational Site	Napoli	Campania
Italy	GSK Investigational Site	Napoli	Campania
Italy	GSK Investigational Site	Orbetello (GR)	Toscana
Italy	GSK Investigational Site	Oviglio (AL)	Piemonte
Italy	GSK Investigational Site	Parabita (LE)	Puglia
Italy	GSK Investigational Site	Perugia	Umbria
Italy	GSK Investigational Site	Perugia	Umbria
Italy	GSK Investigational Site	Perugia	Umbria
Italy	GSK Investigational Site	Ripa (PG)	Umbria
Italy	GSK Investigational Site	Roma	Lazio
Italy	GSK Investigational Site	Roma	Lazio
Italy	GSK Investigational Site	Roma	Lazio
Italy	GSK Investigational Site	Roma	Lazio
Italy	GSK Investigational Site	Roma	Lazio
Italy	GSK Investigational Site	Roma	Lazio
Italy	GSK Investigational Site	Rome
Italy	GSK Investigational Site	Sale (AL)	Piemonte
Italy	GSK Investigational Site	Sassofortino (GR)	Toscana
Italy	GSK Investigational Site	Sesto Calende (VA)	Lombardia
Italy	GSK Investigational Site	Solbiate Olona (VA)	Lombardia
Italy	GSK Investigational Site	Specchia (LE)	Puglia
Italy	GSK Investigational Site	Varese	Lombardia
Italy	GSK Investigational Site	Villalvernia (AL)	Piemonte

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

Italy, 

References & Publications (1)

Salvetti A, Ferrari V, Garofalo R, Gazzaniga P, Guerroni A, Metrucci A, Sessa A, Severi ML, Nati G, Ruggeri M, Rossi A, Cappellari L, Gopala K, Tosatto R, Simone B. Incidence of herpes zoster and postherpetic neuralgia in Italian adults aged =50 years: A prospective study. Prev Med Rep. 2019 Apr 24;14:100882. doi: 10.1016/j.pmedr.2019.100882. eCollection 2019 Jun. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Incidence Rate of Herpes Zoster (HZ) Cases, by Age and Gender	A case of HZ was defined as new unilateral pain (broadly defined to include allodynia and pruritus) accompanied by unilateral rash and no alternative diagnosis. Age ranges were 50-54, 55-59, 60-64, 65-69, 70-74, 75-79 and greater than or equal to (=) 80 years. The incidence rate was expressed as the number of HZ cases per (/) 1000 person-years.	Day 0 to 2 years
Secondary	Percentage of Postherpetic Neuralgia (PHN) Cases Among HZ, Overall	PHN persistence refers to pain occurring or persisting from Day 90 to Day 270 after the rash onset. PHN was assessed via the Zoster Pain Inventory (ZBPI) questionnaire, which includes four pain severity items (worst, least, average, present pain) and seven pain interference items which assess general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. All of the items are rated on an 11-point Likert scale (0-10). For the severity items, 0 = 'no pain' and 10 = 'pain as bad as you can imagine', whereas for the interference items, 0 = 'does not interfere' and 10 = 'completely interferes'.	At Day 90, 180 and 270 after onset of HZ
Secondary	General Medical History of Cases With HZ, Overall	General medical history focused on characteristics such as patient pre-existing condition and diseases (local trauma, diabetes mellitus, liver disease, alcoholism, renal failure/dialysis, emotional problems, stress or depression, blood malignancy, solid malignancy, hematopoetic cell/ bone marrow transplant, solid organ transplantation, HIV infection, hepatitis C under active therapy, autoimmune disease active and under therapy, other).	Between Day 0 and Day 270.
Secondary	Other General Medical History Characteristics for HZ Cases, Overall	Other general medical history characteristics referred to arterial problems, cerebral problems, gastric problems, gastric problems, prostate problems (arterial hypertension and allergic rhinitis, arterial hypertension and pacemaker, arteriopathy and past nun-Hodgkin lymphoma, atrial fibrillation, bronchopathy, cerebral thrombosis, cholecyst, chronic cerebral ischemia, chronic leukemia, chronic obstructive pulmonary disease, epilepsy, gastric lymphoma, gastropathy, hypertension, hypertension and hypothyroidism after surgery, hypertension dyslipidemia and hyperthyroidism, hypothyroidism hypertension, polycythaemia, polycythaemia from 10 years, prostate neoplasm, prostate oral anticoagulant therapy cardiopathy, prostatic cancer, right feet arthralgia, thrombocytopenia, vasculopathy chronic brain).	Between Day 0 and Day 270.
Secondary	Clinical Information of Cases With HZ, Overall	Clinical information of HZ cases referred to experience of any symptoms before rash, actual symptoms before rash (SBR), any complications at initial visit.	Between Day 0 and Day 270
Secondary	Complications Related to HZ Cases, Overall	HZ related complications refer to cutaneous complications (Varicella Zoster Virus [VZV] dissemination, Bacterial superinfection), ocular (Loss of corneal sensation, Keratitis, Scleritis, Uveitis, Iridocyclitis), neurological (Meningo-encephalitis, Cranial nerve palsies, Peripheral nerve palsies, Ramsay-Hunt syndrome, Persistent HZ-related Pain), visceral [Neural extension of VZV infection (bronchitis, esophagitis,cystitis), VZV dissemination (pneumonia, arthritis, hepatitis] and other.	Between Day 0 and Day 270
Secondary	Other Complications Related to HZ Cases, Overall	HZ related other complications refer to axillary lympagenopathy, burning sensation, hypoacusis, itching and rectum pain.	Between Day 0 and Day 270
Secondary	Direct Medical Costs, Direct Non-medical Costs and Indirect Costs	Cost data related to HZ included medication, procedures and referral to hospital/specialist for direct medical costs, transport for direct non-medical costs and missed time from work, sick certificate for the indirect costs.	Up to Day 90
Secondary	Worst Pain Assessment in HZ Subjects	The ZBPI is an assessment tool in the form of a questionnaire completed by the patient that is specifically designed to assess HZ-associated pain and discomfort. the ZBPI includes four pain severity items (worst, least, average, present pain) and seven pain interference items which assess general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. All of the items are rated on an 11-point Likert scale (0-10). For the severity items, 0 = 'no pain' and 10 = 'pain as bad as you can imagine', whereas for the interference items, 0 = 'does not interfere' and 10 = 'completely interferes'. Note: The Day 90 window included assessments between Day 83 and Day 97 relative to day of rash onset.	At Day 90
Secondary	Average Pain Assessment in HZ Subjects	The ZBPI is an assessment tool in the form of a questionnaire completed by the patient that is specifically designed to assess HZ-associated pain and discomfort. the ZBPI includes four pain severity items (worst, least, average, present pain) and seven pain interference items which assess general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. All of the items are rated on an 11-point Likert scale (0-10). For the severity items, 0 = 'no pain' and 10 = 'pain as bad as you can imagine', whereas for the interference items, 0 = 'does not interfere' and 10 = 'completely interferes'. Note: The Day 90 window included assessments between Day 83 and Day 97 relative to day of rash onset.	At Day 90
Secondary	Impact of HZ on Quality of Life as Assessed by the Zoster Pain Inventory	PHN persistence refers to pain occurring or persisting between 90-270 days after the rash onset. PHN was assessed via the Zoster Pain Inventory (ZBPI) questionnaire, which includes four pain severity items (worst, least, average, present pain) and seven pain interference items which assess general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. All of the items are rated on an 11-point Likert scale (0-10). For the severity items, 0 = 'no pain' and 10 = 'pain as bad as you can imagine', whereas for the interference items, 0 = 'does not interfere' and 10 = 'completely interferes'.	At Day 0, 15, 30, 60, 90
Secondary	Impact of HZ on Quality of Life as Assessed by the EuroQoL-Five Digits	EuroQoL-Five Digits (EQ-5D) is a standardised instrument for use as a measure of health outcome and is designed for self-completion by respondents. Its current format is 3-level and 5 dimensional (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The EQ-5D index was derived from the ratings recorded every 3 months for each of the five individual items (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The EQ-5D index/scale goes from 0 (worst health state) to 1 (perfect health state).	At Day 0, 15, 30, 60, 90
Secondary	PHN Direct Medical Costs, Direct Non-medical Costs and Indirect Costs by Payer/Societal Perspective	Cost data related to HZ included medication, procedures and referral to hospital/specialist for direct medical costs, transport for direct non-medical costs and missed time from work, sick certificate for the indirect costs.	Between Day 90 and Day 270
Secondary	Worst Pain Assessment in PHN Subjects	The ZBPI is an assessment tool in the form of a questionnaire completed by the patient that is specifically designed to assess HZ-associated pain and discomfort. the ZBPI includes four pain severity items (worst, least, average, present pain) and seven pain interference items which assess general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. All of the items are rated on an 11-point Likert scale (0-10). For the severity items, 0 = 'no pain' and 10 = 'pain as bad as you can imagine', whereas for the interference items, 0 = 'does not interfere' and 10 = 'completely interferes'. Note: The Day 90 window included assessments between Day 83 and Day 97 relative to day of rash onset.	At Day 90
Secondary	Average Pain Assessment in PHN Subjects	The ZBPI is an assessment tool in the form of a questionnaire completed by the patient that is specifically designed to assess HZ-associated pain and discomfort. The ZBPI includes four pain severity items (worst, least, average, present pain) and seven pain interference items which assess general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. All of the items are rated on an 11-point Likert scale (0-10). For the severity items, 0 = 'no pain' and 10 = 'pain as bad as you can imagine', whereas for the interference items, 0 = 'does not interfere' and 10 = 'completely interferes'. Note: The Day 90 window included assessments between Day 83 and Day 97 relative to day of rash onset.	At Day 90
Secondary	Impact of PHN on Quality of Life as Assessed by the Zoster Pain Inventory	PHN persistence refers to pain occurring or persisting between 90-270 days after the rash onset. PHN was assessed via the Zoster Pain Inventory (ZBPI) questionnaire, which includes four pain severity items (worst, least, average, present pain) and seven pain interference items which assess general activity, mood, walking ability, work, relations with others, sleep and enjoyment of life. All of the items are rated on an 11-point Likert scale (0-10). For the severity items, 0 = 'no pain' and 10 = 'pain as bad as you can imagine', whereas for the interference items, 0 = 'does not interfere' and 10 = 'completely interferes'.	At Day 0, 15, 30, 60, 90
Secondary	Impact of PHN on Quality of Life as Assessed by the EuroQoL-Five Digits	EuroQoL-Five Digits (EQ-5D) is a standardised instrument for use as a measure of health outcome and is designed for self-completion by respondents. Its current format is 3-level and 5 dimensional (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The EQ-5D index was derived from the ratings recorded every 3 months for each of the five individual items (mobility, self-care, usual activities, pain/discomfort and anxiety/depression). The EQ-5D index was 0 (worst health state) to 1 (best health state).	At Day 0, 15, 30, 60, 90